MCID: OLG002
MIFTS: 56

Oligodendroglioma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Oligodendroglioma

Aliases & Descriptions for Oligodendroglioma:

Name: Oligodendroglioma 12 50 56 29 52 42 14 69
Oligodendroglial Neoplasm 12 69
Well Differentiated Oligodendroglioma 69
Oligodendroglial Tumors 52
Oligodendroglial Tumor 12

Characteristics:

Orphanet epidemiological data:

56
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 42 D009837
NCIt 47 C6960
Orphanet 56 ORPHA251627
UMLS via Orphanet 70 C0028945
ICD10 via Orphanet 34 C71.9

Summaries for Oligodendroglioma

NIH Rare Diseases : 50 oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. they can be low-grade (grade ii) or high-grade (grade iii, also called anaplastic). while they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. they are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. they tend to grow slowly and may be present for many years before they are diagnosed. common symptoms include seizures, headaches and changes in personality. other symptoms vary by the size and location of the tumor. the exact cause of opigodendrogliomas is unknown. some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. recurrent tumors may need additional surgery, radiation and chemotherapy. last updated: 8/8/2016

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to spinal cord oligodendroglioma and brain oligodendroglioma. An important gene associated with Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are HTLV-I infection and DNA Damage Response. The drugs Carmustine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and spinal cord, and related phenotypes are Decreased viability in esophageal squamous lineage and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 71 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
id Related Disease Score Top Affiliating Genes
1 spinal cord oligodendroglioma 33.3 CDKN2A PCNA TP53
2 brain oligodendroglioma 33.2 GFAP IDH1 OLIG2 SYP TP53 TP73
3 adult oligodendroglioma 30.7 CDKN2A CDKN2C CIC EGFR ENO2 GFAP
4 neurilemmoma 29.7 IDH1 IDH2
5 anaplastic oligodendroglioma 12.0
6 corpus callosum oligodendroglioma 12.0
7 mixed oligodendroglioma-astrocytoma 11.9
8 childhood oligodendroglioma 11.8
9 mixed astrocytoma-ependymoma-oligodendroglioma 11.8
10 oligoastrocytoma 11.7
11 glioma susceptibility 1 11.6
12 glioma 11.2
13 glioma susceptibility 9 10.8
14 glioma susceptibility 2 10.8
15 glioblastoma 3 10.8
16 optic disk drusen 10.4 IDH1 IDH2
17 liver fibrosarcoma 10.4 GFAP TP53
18 papillary tumor of the pineal region 10.4 GFAP IDH1 SYP
19 enterovesical fistula 10.4 IDH1 IDH2
20 diabetes hypogonadism deafness mental retardation 10.4 GFAP SYP
21 adenofibroma 10.4 GFAP IDH1 SYP
22 cervical adenoid cystic carcinoma 10.4 GFAP TP53
23 clear cell adenofibroma 10.4 CDKN2A TP53
24 testis refractory cancer 10.4 IDH1 IDH2 TP53
25 cystinosis, nephropathic 10.4 IDH1 IDH2 TP53
26 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.4 GFAP IDH1 SYP
27 bronchial mucus gland adenoma 10.4 GFAP IDH2 PTEN
28 middle ear disease 10.4 GFAP IDH1 TP53
29 bile duct clear cell adenocarcinoma 10.4 GFAP IDH2 TP53
30 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
31 ophn1 syndrome 10.4 GFAP IDH2 MGMT
32 epidermal appendage tumor 10.4 GFAP PTEN SYP
33 cystic lymphangioma 10.3 IDH1 IDH2 PTEN
34 cervical benign neoplasm 10.3 GFAP SYP TP53
35 dysgerminoma of ovary 10.3 GFAP OLIG2 SYP
36 clear cell meningioma 10.3 GFAP SYP TP53
37 aneurysm of sinus of valsalva 10.3 GFAP PTEN SYP
38 vulvar benign neoplasm 10.3 GFAP SYP TP53
39 adult syndrome 10.3 PTEN TP53 TP73
40 mast-cell sarcoma 10.3 GFAP SYP TP53
41 olfactory neuroblastoma 10.3 GFAP SYP TP53
42 melanotic neurilemmoma 10.3 GFAP IDH1 SYP
43 children's interstitial lung disease 10.3 GFAP MBP SYP
44 pineoblastoma 10.3 GFAP SYP TP53
45 t-cell adult acute lymphocytic leukemia 10.3 IDH1 IDH2 SYP
46 acrocallosal syndrome 10.3 IDH1 IDH2
47 paraphimosis 10.3 CDKN2A SYP TP53
48 astrocytoma 10.3
49 wolffian adnexal neoplasm 10.3 EGFR TP53
50 arthus reaction 10.3 GFAP SYP TP53

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.9 CDKN2A CDKN2C CIC GFAP IDH1 IDH2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 PTEN CDKN2A TP53 CIC TP73 PCNA
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 PTEN CDKN2A TP53 CIC TP73 PCNA
4 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 CIC MGMT PCNA POT1 TP53 TP73

MGI Mouse Phenotypes related to Oligodendroglioma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.31 UGT8 CDKN2A CDKN2C CIC EGFR ENO2
2 behavior/neurological MP:0005386 10.3 CDKN2A CDKN2C CIC ENO2 GFAP LRIG2
3 mortality/aging MP:0010768 10.25 CDKN2A CDKN2C CIC EGFR GFAP IDH1
4 cellular MP:0005384 10.21 CDKN2A CDKN2C EGFR ENO2 GFAP LRIG2
5 immune system MP:0005387 10.15 LRIG2 MBP PCNA PTEN TP53 TP73
6 nervous system MP:0003631 10.03 PTEN SYP TP53 TP73 UGT8 CDKN2A
7 neoplasm MP:0002006 9.96 TP53 TP73 CDKN2A CDKN2C EGFR IDH2
8 respiratory system MP:0005388 9.7 CIC EGFR ENO2 IDH1 MGMT OLIG2
9 vision/eye MP:0005391 9.23 CDKN2A EGFR GFAP MBP OLIG2 PTEN

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved Phase 3,Phase 1,Phase 2 154-93-8 2578
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
10
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
12
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
13
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
16
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
17
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Ondansetron Approved Phase 3 99614-02-5 4595
21
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 3,Phase 1,Phase 2
35 Etoposide phosphate Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 3,Phase 2
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
39 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 3,Phase 2,Phase 1
41 Analgesics Phase 3,Phase 2,Phase 1
42 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
43 Liver Extracts Phase 3,Phase 2,Phase 1
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Keratolytic Agents Phase 3,Phase 1,Phase 2
46 Adjuvants, Anesthesia Phase 3
47 Analgesics, Opioid Phase 3
48 Anesthetics Phase 3,Phase 1
49 Anesthetics, General Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 360)
id Name Status NCT ID Phase
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3
5 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
9 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
10 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3
11 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3
12 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Recruiting NCT00978458 Phase 3
13 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3
14 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3
15 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
16 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
18 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
19 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Unknown status NCT00003472 Phase 2
21 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
22 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2
23 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2
24 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2
25 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
26 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2
27 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
28 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
29 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2
30 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2
31 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Unknown status NCT01026493 Phase 1, Phase 2
32 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2
33 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2
34 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2
35 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2
36 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
37 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2
38 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2
39 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2
40 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2
41 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2
42 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2
43 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2
44 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2
45 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2
46 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2
47 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2
48 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2
49 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed NCT00392171 Phase 2
50 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

id Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

39
Brain, Temporal Lobe, Spinal Cord, Bone, Endothelial, Bone Marrow, Breast

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 686)
id Title Authors Year
1
Pinpointing Cancer Stem Cells in Oligodendroglioma. ( 27864226 )
2017
2
CNS cancer: Tracing stem cells in oligodendroglioma. ( 27874063 )
2017
3
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
4
Papilloedema secondary to oligodendroglioma. ( 27489047 )
2016
5
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FEATURES OF A MULTIFOCAL OLIGODENDROGLIOMA IN THE SPINAL CORD AND BRAIN OF A DOG. ( 27490488 )
2016
6
Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. ( 27347150 )
2016
7
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
8
World Health Organization Grade II Oligodendroglioma Occurring after Successful Treatment for Childhood Acute Lymphoblastic Leukemia. ( 27867928 )
2016
9
Imaging of oligodendroglioma. ( 26849038 )
2016
10
Sarcoma-like tumor originating from oligodendroglioma. ( 27333891 )
2016
11
Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma. ( 27862886 )
2016
12
Glioblastoma with oligodendroglioma component in a ewe. ( 27154317 )
2016
13
Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma. ( 27900202 )
2016
14
Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. ( 27502573 )
2016
15
Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. ( 27466523 )
2016
16
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
17
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. ( 27251883 )
2016
18
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. ( 27812792 )
2016
19
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. ( 26206478 )
2016
20
Synchronous thymoma and oligodendroglioma: A rare association. ( 26957188 )
2016
21
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
22
Granular cells in oligodendroglioma suggest a neoplastic change rather than a reactive phenomenon: case report with molecular characterisation. ( 27738816 )
2016
23
High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. ( 26960282 )
2016
24
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
25
Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. ( 26757882 )
2016
26
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. ( 27974037 )
2016
27
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. ( 27806376 )
2016
28
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
29
Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. ( 27623848 )
2016
30
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
31
Oligodendroglial cell proliferation arising in an ovarian mature cystic teratoma. Clinicopathological, inmunohistochemical, and ultrastructural study of a case that may represent an oligodendroglioma. ( 28029275 )
2016
32
Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. ( 25813856 )
2015
33
A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging. ( 26622514 )
2015
34
Primary intraventricular oligodendroglioma: A case report of the usefulness of Olig2 immunohistochemistry for diagnosis. ( 26079719 )
2015
35
TCF12 is mutated in anaplastic oligodendroglioma. ( 26068201 )
2015
36
Oligodendroglioma presenting as chronic mania. ( 26300601 )
2015
37
Alien limb syndrome secondary to multimodal treatment of recurrent oligodendroglioma. ( 26094559 )
2015
38
Primary Spinal Cord Oligodendroglioma with Postoperative Adjuvant Radiotherapy: A Case Report. ( 26512274 )
2015
39
Proteomics analysis of human oligodendroglioma proteome. ( 26002447 )
2015
40
Characterization of Inflammatory Changes Associated with Canine Oligodendroglioma. ( 26145723 )
2015
41
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. ( 26243269 )
2015
42
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. ( 25427834 )
2015
43
Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. ( 25794445 )
2015
44
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. ( 26545048 )
2015
45
Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. ( 26232204 )
2015
46
Ependymal tumors with oligodendroglioma like clear cells: Experience from a tertiary care hospital in Pakistan. ( 26664928 )
2015
47
Recurrent Oligodendroglioma Treated with Acupuncture and Pharmacopuncture. ( 26100069 )
2015
48
Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. ( 26108672 )
2015
49
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. ( 26018682 )
2015
50
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( 26352098 )
2015

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 2030)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10660 TP53 central nervous system,brain,glioma,anaplastic c.818G>A p.R273H 5
2 COSM43765 TP53 central nervous system,brain,glioma,anaplastic c.727A>C p.M243L 5
3 COSM43745 TP53 central nervous system,brain,glioma,anaplastic c.918A>T p.R306R 5
4 COSM10812 TP53 central nervous system,brain,glioma,anaplastic c.722C>T p.S241F 5
5 COSM10654 TP53 central nervous system,brain,glioma,anaplastic c.637C>T p.R213* 5
6 COSM11133 TP53 central nervous system,brain,glioma,anaplastic c.725G>C p.C242S 5
7 COSM43747 TP53 central nervous system,brain,glioma,anaplastic c.872A>G p.K291R 5
8 COSM43903 TP53 central nervous system,brain,glioma,anaplastic c.470T>G p.V157G 5
9 COSM10891 TP53 central nervous system,brain,glioma,anaplastic c.814G>A p.V272M 5
10 COSM6906 TP53 central nervous system,brain,glioma,anaplastic c.672+1G>A p.? 5
11 COSM10777 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 5
12 COSM43939 TP53 central nervous system,brain,glioma,anaplastic c.632C>T p.T211I 5
13 COSM44327 TP53 central nervous system,brain,glioma,anaplastic c.518T>C p.V173A 5
14 COSM10726 TP53 central nervous system,brain,glioma,anaplastic c.856G>A p.E286K 5
15 COSM43742 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 5
16 COSM10651 TP53 central nervous system,brain,glioma,anaplastic c.530C>G p.P177R 5
17 COSM10645 TP53 central nervous system,brain,glioma,anaplastic c.527G>T p.C176F 5
18 COSM10750 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 5
19 COSM10834 TP53 central nervous system,brain,glioma,anaplastic c.711G>A p.M237I 5
20 COSM44623 TP53 central nervous system,brain,glioma,anaplastic c.487T>A p.Y163N 5
21 COSM43743 TP53 central nervous system,brain,glioma,anaplastic c.914A>G p.K305R 5
22 COSM43843 TP53 central nervous system,brain,glioma,anaplastic c.817C>G p.R273G 5
23 COSM11564 TP53 central nervous system,brain,glioma,anaplastic c.742C>G p.R248G 5
24 COSM44570 TP53 central nervous system,brain,glioma,anaplastic c.332T>G p.L111R 5
25 COSM43679 TP53 central nervous system,brain,glioma,anaplastic c.531C>T p.P177P 5
26 COSM11087 TP53 central nervous system,brain,glioma,anaplastic c.472C>G p.R158G 5
27 COSM11198 TP53 central nervous system,brain,glioma,anaplastic c.785G>T p.G262V 5
28 COSM43708 TP53 central nervous system,brain,glioma,anaplastic c.422G>A p.C141Y 5
29 COSM44606 TP53 central nervous system,brain,glioma,anaplastic c.665C>T p.P222L 5
30 COSM44262 TP53 central nervous system,brain,glioma,anaplastic c.808T>C p.F270L 5
31 COSM11196 TP53 central nervous system,brain,glioma,anaplastic c.734G>T p.G245V 5
32 COSM44910 TP53 central nervous system,brain,glioma,anaplastic c.403T>A p.C135S 5
33 COSM46287 TP53 central nervous system,brain,glioma,anaplastic c.557A>G p.D186G 5
34 COSM43545 TP53 central nervous system,brain,glioma,anaplastic c.503A>G p.H168R 5
35 COSM44829 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 5
36 COSM11090 TP53 central nervous system,brain,glioma,anaplastic c.541C>T p.R181C 5
37 COSM43973 TP53 central nervous system,brain,glioma,anaplastic c.718A>G p.S240G 5
38 COSM43748 TP53 central nervous system,brain,glioma,anaplastic c.783T>C p.S261S 5
39 COSM5113 PTEN central nervous system,brain,glioma,anaplastic c.314G>A p.C105Y 5
40 COSM5110 PTEN central nervous system,brain,glioma,anaplastic c.632G>A p.C211Y 5
41 COSM5149 PTEN central nervous system,brain,glioma,anaplastic c.511C>T p.Q171* 5
42 COSM5211 PTEN central nervous system,brain,glioma,anaplastic c.376G>C p.A126P 5
43 COSM5335 PTEN central nervous system,brain,glioma,anaplastic c.1211G>C p.*404S 5
44 COSM5232 PTEN central nervous system,brain,glioma,anaplastic c.44G>T p.R15I 5
45 COSM5230 PTEN central nervous system,brain,glioma,anaplastic c.758T>A p.I253N 5
46 COSM5298 PTEN central nervous system,brain,glioma,anaplastic c.19G>T p.E7* 5
47 COSM5187 PTEN central nervous system,brain,glioma,anaplastic c.392C>A p.T131N 5
48 COSM5267 PTEN central nervous system,brain,glioma,anaplastic c.820T>G p.W274G 5
49 COSM249139 PIK3CA central nervous system,brain,glioma,anaplastic c.3013A>G p.M1005V 5
50 COSM249141 PIK3CA central nervous system,brain,glioma,anaplastic c.3023C>G p.S1008C 5

Copy number variations for Oligodendroglioma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1 12.29 CDKN2A CDKN2C PCNA TP53
2
Show member pathways
12.23 CDKN2A PTEN TP53 TP73
3 12.22 CDKN2A CDKN2C PCNA TP53
4
Show member pathways
12.2 EGFR PCNA PTEN TP53
5 12.2 CDKN2A CDKN2C MGMT PCNA TP53 TP73
6 11.89 EGFR GFAP MBP TP53
7 11.84 CDKN2A PTEN TP53 TP73
8 11.78 CDKN2A PCNA PTEN TP53
9 11.74 GFAP MBP OLIG1 OLIG2
10 11.68 CDKN2A MGMT PCNA PTEN TP53
11 11.58 CDKN2A EGFR TP53
12 11.57 GFAP OLIG1 OLIG2 SYP
13 11.47 EGFR PCNA PTEN TP53 TP73
14 11.44 EGFR IDH1 PTEN TP53
15 11.41 CDKN2A EGFR TP53
16 11.18 CDKN2A CDKN2C TP53
17 11.07 CDKN2A EGFR MGMT PTEN TP53
18
Show member pathways
10.92 CDKN2A TP53 TP73
19
Show member pathways
10.69 IDH1 IDH2

GO Terms for Oligodendroglioma

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.62 CDKN2A CDKN2C TP53 TP73
2 cellular response to UV GO:0034644 9.58 PCNA TP53 TP73
3 response to organic cyclic compound GO:0014070 9.56 EGFR IDH1 MGMT PTEN
4 DNA ligation GO:0006266 9.52 MGMT PCNA
5 replicative senescence GO:0090399 9.51 CDKN2A TP53
6 negative regulation of axon regeneration GO:0048681 9.49 LRIG2 PTEN
7 mitotic G1 DNA damage checkpoint GO:0031571 9.48 TP53 TP73
8 negative regulation of cardiac muscle cell proliferation GO:0060044 9.46 PTEN TP73
9 regulation of axon regeneration GO:0048679 9.43 LRIG2 PTEN
10 isocitrate metabolic process GO:0006102 9.37 IDH1 IDH2
11 oligodendrocyte differentiation GO:0048709 9.33 CDKN2C OLIG1 OLIG2
12 positive regulation of DNA repair GO:0045739 9.13 EGFR MGMT PCNA
13 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 EGFR GFAP PCNA PTEN SYP TP53
2 magnesium ion binding GO:0000287 9.67 ENO2 IDH1 IDH2 PTEN
3 damaged DNA binding GO:0003684 9.5 PCNA TP53 TP73
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.43 CDKN2A CDKN2C
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
6 protein kinase binding GO:0019901 9.1 CDKN2A CDKN2C EGFR PTEN TP53 TP73
7 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
8 DNA binding GO:0003677 10.06 CDKN2A CIC MGMT OLIG1 OLIG2 PCNA

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....